Trovagene
1 / 1
Oncology
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
Trovagene
PR-M01-19-NI-089Jan 31, 2019
Drug Development
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Trovagene
PR-M01-19-NI-073Jan 25, 2019
Financial Results
Trovagene Announces Third Quarter 2018 Highlights and Financial Results
Trovagene
PR-M11-18-NI-037Nov 12, 2018
Clinical Trial
Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
Trovagene
PR-M09-18-NI-061Sep 20, 2018
Approval
Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Trovagene
PR-M09-18-NI-048Sep 18, 2018
Orphan Drug
Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug
Trovagene
PR-M08-18-NI-032Aug 09, 2018
1 / 1